Hillsdale Investment Management Inc. Increases Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Hillsdale Investment Management Inc. raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 65,213.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 542,100 shares of the biotechnology company’s stock after buying an additional 541,270 shares during the period. Hillsdale Investment Management Inc. owned about 0.26% of BioCryst Pharmaceuticals worth $4,077,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of BCRX. Fisher Asset Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of BioCryst Pharmaceuticals by 472.0% in the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after buying an additional 409,938 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares during the period. Cinctive Capital Management LP purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $2,082,000. Finally, Two Sigma Advisers LP lifted its position in shares of BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 261,500 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.98 on Friday. The business’s 50 day moving average price is $8.12 and its 200 day moving average price is $7.82. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -13.08 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. During the same quarter last year, the firm posted $0.28 earnings per share. The company’s revenue was up 40.8% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.